This report was first published by Endpoints News. To see the original version, click here
Eli Lilly is making its biggest acquisition in years, devoting part of its GLP-1 cash influx to buy Centessa Pharmaceuticals and its experimental medicines for sleep disorders and neurological conditions.
The pharma giant will devote $6.3 billion upfront and up to $1.5 billion in contingent value rights to acquire Centessa and its orexin receptor 2 (OX2R) agonists. The deal is for $38 per share $CNTA upfront in cash. It also includes multiple CVRs upon certain regulatory approvals.
您已阅读22%（575字），剩余78%（1993字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。